Tirzepatide vs. Semaglutide: What SURMOUNT-5 Settled (2026)

If you're on a GLP-1 or thinking about starting one, you've almost certainly run the comparison in your head. Zepbound or Wegovy. Tirzepatide or semaglutide. Which one drops more weight? For a few years the only answer anyone could honestly give was a shrug dressed up as analysis — two separate trials, two different sets of people, two starting lines that never lined up. You couldn't really compare them, so people compared them anyway and called it a verdict.

SURMOUNT-5 ended that guessing game. It put both drugs in the same trial, against the same kind of people, measured the same way, and let the scale settle it. The answer it returned is clear, and it deserves to be said plainly. It's also only half of what you need before you change anything, which is why the other half gets just as much room here as the headline.

So which one wins? The short version

Tirzepatide lost more weight. Not by a hair, and not by an amount you can wave away. In SURMOUNT-5, people on tirzepatide lost a mean of 20.2% of their body weight at 72 weeks, against 13.7% for those on semaglutide, with the difference landing well past the threshold of statistical chance (P less than 0.001). That's a real gap, and it points in one direction.

Here's the catch that the headline leaves out: 13.7% is not a loser's number. A drug that reliably takes more than a tenth of a person's body weight off would have looked like science fiction a decade ago. So the honest framing isn't "one drug works, the other doesn't." It's "both work, and one worked more on average." Hold onto that word — average. It's going to do a lot of quiet work later, because the trial measured a crowd, and you are not a crowd.

Why a head-to-head trial settles more

Before SURMOUNT-5, the comparison everyone made went like this: tirzepatide posted big numbers in its SURMOUNT trials, semaglutide posted slightly smaller numbers in its STEP trials, so tirzepatide must be stronger. Reasonable on the surface, shaky underneath.

The problem is that two separate trials are never really comparable. The people enrolled differ. The starting weights differ. The diet-and-exercise instructions, the dropout rates, the way side effects get counted — all of it differs. Lining up a percentage from one trial against a percentage from another and declaring a winner is a sportswriter's move, not a scientist's. It feels like a comparison. It isn't one.

A head-to-head trial removes every one of those excuses. Same protocol, same clinic visits, same rules, with people randomly sorted into one drug or the other so the two groups start as mirror images. When a difference shows up at the end, you can actually attribute it to the drugs — not to some quirk of who happened to enroll where. That's the whole reason this trial carries weight that a stack of indirect comparisons never could.

A direct comparison is the difference between "these two numbers look different" and "this drug did more than that drug, in the same people, under the same conditions." Only the second one is a finding. Everything before SURMOUNT-5 was the first kind, dressed up to look like the second.

How SURMOUNT-5 was built

The design was refreshingly direct. Take adults living with obesity, randomize them to one drug or the other, run it for 72 weeks — about sixteen months — and weigh the results. A total of 751 people were randomized, both drugs given as a once-weekly injection.

One detail matters more than it looks. Each drug was pushed to its maximum tolerated dose: tirzepatide at 10 mg or 15 mg, semaglutide at 1.7 mg or 2.4 mg. That's the even-handed version of the question. It isn't "a low dose of one against a high dose of the other" — it's each medicine doing the most it can do, then comparing the ceilings. If you've wondered whether the gap is just a dosing artifact, this design is the answer: it was built specifically to rule that out.

The 72-week window earns a mention too. Weight loss on these drugs doesn't finish in a month or even a season — the curve keeps bending for the better part of a year and a half. A trial that quit at twelve weeks would have caught a sprint and missed the marathon. This one stayed long enough to see where people actually landed.

The result: tirzepatide came out ahead

Here's the headline with its full sentence attached. At week 72, the least-squares mean change in body weight was a 20.2% loss with tirzepatide and a 13.7% loss with semaglutide. The confidence intervals — the statistical fences around each number — sat at −21.4 to −19.1 for tirzepatide and −14.9 to −12.6 for semaglutide. They don't overlap, the P-value came in under 0.001, and the conclusion is hard to argue with: in the same trial, on the same kind of people, tirzepatide took off more.

What does 6.5 percentage points feel like off the page? Picture someone who started around 100 kg, roughly 220 lb. On the semaglutide arm, 13.7% is somewhere near 14 kg — call it 30 lb. On the tirzepatide arm, 20.2% is closer to 20 kg, around 44 lb. Both of those would change how a person feels walking up a flight of stairs. One of them changed it a bit more. (Those are illustrative conversions from the percentages, not figures the trial reported in kilograms — every person's starting weight bends the math.)

Two non-overlapping confidence intervals is the quiet part that statisticians get excited about. It means the difference wasn't a near-miss that could flip in a re-run. The trial didn't just find tirzepatide ahead — it found it ahead with room to spare.

That's the must-know fact of this whole piece: 20.2% versus 13.7%, in a direct comparison. Everything after this is about what that does and doesn't tell you.

Beyond the scale: waist and responders

Weight is the headline, but it isn't the only thing that moved, and the other measures tell the same story. Waist circumference — a decent stand-in for the visceral fat that sits around your organs and does the real metabolic damage — dropped 18.4 cm on tirzepatide against 13.0 cm on semaglutide, again clearing P less than 0.001. So the tirzepatide advantage wasn't only on the scale. It showed up at the tape measure too.

Then there's the question of who got the big results, not just what the averages were. Trials report this as responder rates: the share of people who cleared specific milestones. People on tirzepatide were more likely than those on semaglutide to hit weight reductions of at least 10%, at least 15%, at least 20%, and at least 25%. At every rung of that ladder, the tirzepatide group had more people standing on it.

Notice the careful wording on responders: "more people," not "everyone." The averages and the milestones both lean the same way, which makes the trial's signal consistent rather than lucky. But a milestone is a population fact. It tells you how the crowd sorted out. It does not tell you which rung you, specifically, would land on — and that's the seam where the headline and your real life start to pull apart.

"Won on average" isn't "won for you"

This is the part the comparison threads on Reddit almost always skip, and it's the part that matters most. A trial average is a fact about a group. It is not a forecast for an individual. The 20.2% figure is what happened across everyone on tirzepatide — and "everyone" includes people who lost far more and people who lost far less. Your number lives somewhere on that spread, and the spread is wide.

Several things outside the efficacy column decide which drug is the better fit, and the trial doesn't rank any of them for you:

• Tolerability. Both drugs share the GLP-1 side-effect family — nausea, constipation, the early queasy weeks. Some people sail through one and struggle on the other. The drug you can actually stay on beats the drug that looks stronger on paper but sends you reaching for crackers at 3 p.m.
• Other conditions. What else you're managing — type 2 diabetes, heart concerns, sleep apnea — shapes which medicine your clinician reaches for first, sometimes regardless of the headline percentage.
• Cost and coverage. Two drugs with similar list prices can land in completely different places once your formulary, prior authorization, and copay get involved. The cheaper-to-you drug is sometimes the one that lost the trial.
• Access. Supply, your plan's preferred-drug list, and what your prescriber is set up to write all narrow the field before efficacy ever gets a say.

A stronger average is a genuine point in tirzepatide's favor. It is not a coupon that overrides your tolerability, your wallet, and your other conditions. The right drug is the one that fits the whole picture — and the whole picture is yours, not the trial's.

So if you're already on semaglutide and doing well — losing weight, tolerating it, affording it — SURMOUNT-5 is not an order to switch. It's one input. "Tirzepatide wins on average" and "you personally should change drugs" are different sentences, and only a clinician who knows your history can connect them.

The safety borders both drugs share

It would be easy to walk away thinking the only difference that matters is the efficacy gap. On safety, the more honest takeaway is how much these two have in common. They are cousins, and they carry the same family warnings.

On the US FDA label, both carry a boxed warning — the most serious kind the FDA issues — for thyroid C-cell tumors. And both are contraindicated, meaning off the table entirely, for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The exact wording varies by country, so check your own regulator's label, but the underlying caution travels across markets. This isn't a "weigh the pros and cons" situation. If that history runs in your family, this whole class is a hard no, and it belongs at the very top of the first conversation — not buried in the fine print.

There's a shared GI warning too. Acute pancreatitis, including serious cases, has been reported in people taking GLP-1 receptor agonists, this pair among them. The standard guidance is blunt: if pancreatitis is suspected, the medicine is stopped. Severe, persistent abdominal pain is not a side effect to wait out — it's a call-your-doctor signal, for either drug.

The reason this section exists is to head off a specific mistake. When one drug "wins" a comparison, it's tempting to read the other as the riskier choice by default. That's not what SURMOUNT-5 showed. The efficacy numbers differ. The core safety boundaries are shared. Neither drug is the "safe one" against a "dangerous one" — they sit on the same map.

Access and cost, in plain terms

A trial measures what a drug can do under ideal conditions. Your pharmacy measures what you can get, and the two don't always agree. In the United States, both of these are brand-name medicines with no generic version — semaglutide for weight management sells as Wegovy (FDA-approved for obesity in 2021), tirzepatide as Zepbound (FDA-approved for obesity in 2023) — and the list prices for the weekly obesity doses run in the four figures per month before any insurance touches them.

One caveat for readers outside the US: those brand names and obesity indications are specific to the FDA. In many markets tirzepatide is sold only as a diabetes brand (the Mounjaro family), with its obesity use not yet approved or still under review by the local regulator — the EMA, MHRA, Health Canada, or your own agency. So before you assume you can be prescribed either of these for weight management where you live, check what your regulator has cleared.

That sticker number is rarely what anyone pays, which is the whole point. The path from list price to your actual cost runs through your plan's formulary, a prior authorization, and whether you land on a copay or coinsurance — different things that produce wildly different bills. Two drugs that look similarly priced on paper can split far apart once your specific coverage gets involved, and that split sometimes outweighs a few percentage points of trial efficacy.

None of this is a reason to chase a price down some gray-market channel — counterfeit and compounded products are a separate, real hazard, and they're not the same as the approved drug. The grown-up move is to ask your plan for the formulary status of each drug, and let your prescriber match the medicine to both your body and your budget. The drug you can sustain for sixteen months beats the one you abandon at month three because the second refill stunned you.

What to bring to your doctor

If you're going to have this conversation — and a comparison like this one is worth raising — a little prep makes it land better. You want to walk in with your situation, not just a headline percentage.

A few things worth putting on the table:

1. Your goal and your history. How much you're aiming to lose, what you've tried, and how your body handled it. The average from a trial is a starting point, not your prescription.
2. Family thyroid history. Any MTC or MEN 2 in your family is the first gate, not an afterthought. Lead with it.
3. Your other conditions. Diabetes, heart issues, sleep apnea — these can tilt the choice as much as the efficacy gap does.
4. What your plan covers. Which drug your formulary prefers, and what the real out-of-pocket cost looks like for each.
5. Side-effect tolerance. An honest read on how you'd handle a rough few weeks, and whether that changes the calculus for you.

The best question isn't "which drug is stronger." It's "which of these fits me — my history, my coverage, my life — well enough that I'll still be taking it a year from now." Staying power, not just trial power, is what turns a number into a result.

The point of all this isn't to send you in ready to argue. It's to make the appointment a conversation between two people who both know the picture, instead of you nodding along to a recommendation you can't quite evaluate.

The bottom line

Strip away the noise and SURMOUNT-5 is easy to summarize. In a direct, head-to-head trial of 751 people over 72 weeks, tirzepatide produced a mean weight loss of 20.2% against 13.7% for semaglutide — a real, statistically solid advantage that showed up on the scale, at the waistline, and across every responder milestone. That is a genuine finding, and it earns tirzepatide its average edge.

What it doesn't earn is a one-size-fits-all instruction. Both drugs are powerful. Both carry the same thyroid and pancreatitis warnings. And "better on average" is not the same as "better for you," because tolerability, your other conditions, cost, and access all sit outside the efficacy column and often decide more than the percentage does. The strongest drug on paper and the right drug for your life are not guaranteed to be the same one.

Everything here comes from published clinical-trial and peer-reviewed data, not from a testimonial or a sales pitch — and whether tirzepatide, semaglutide, or neither fits your situation is a question for a clinician who can see your whole history. So take the number with you, but don't let it decide for you. A figure like 20.2% earns its place at the start of that appointment, not at the end of your own.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app